AMGN Announcement: Kessler Topaz Meltzer & Check, LLP Announces Investor Securit… – Press Release

[ad_1]

RADNOR, Pa., April 23, 2023 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”) AMGN. The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects. As a result of Amgen’s materially misleading statements and omissions to the public, Amgen’s investors have suffered significant losses.

CLICK HERE TO SUBMIT YOUR AMGEN LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/amgen-inc?utm_source=PR&utm_medium=link&utm_campaign=amgn&mktm=r

TO VIEW OUR VIDEO, PLEASE CLICK HERE

LEAD PLAINTIFF DEADLINE: MAY 12, 2023

CLASS PERIOD: JULY 29, 2020 THROUGH APRIL 27, 2022

CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Jonathan Naji, Esq. at (484) 270-1453 or via email at info@ktmc.com  

Kessler Topaz is one of the world’s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.

AMGEN’S ALLEGED MISCONDUCT
On July 29, 2020, Amgen filed its 10-Q with the SEC wherein it noted the company’s ongoing tax dispute the U.S. government but assured investors that existing accruals were “appropriate” and did not disclose any meaningful accrual for tax liabilities associated with this ongoing tax dispute.

Then, on August 3, 2021, Amgen disclosed, for the first time, massive outstanding tax liabilities sought by the IRS. The release stated that Amgen had received a Notice of Deficiency from…

[ad_2]